Medications

Could nonprofit drug companies cut sky-high prices?

(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Cardiology

Outcomes-based pricing doesn't cut costs of PCSK9 inhibitors

(HealthDay)—Outcomes-based pricing does not reduce the costs of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, according to a research letter published online April 3 in the Annals of Internal Medicine.

Medications

Drug makers engage in 'co-opetition' through drug middlemen

Prescription drug consumers confounded by the cost of their medications can get a peek behind the curtain thanks to new Washington University in St. Louis research into the complex "co-opetition"—cooperation and competition—among ...

page 25 from 40